|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kawai M, Komiyama H, Hosoya M, Okubo H,
Fujii T, Yokoyama N, Sato C, Ueyama T, Okuzawa A, Goto M, et al:
Impact of chromosome 17q deletion in the primary lesion of
colorectal cancer on liver metastasis. Oncol Lett. 12:4773–4778.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zong Z, Zhou T, Rao L, Jiang Z, Li Y, Hou
Z, Yang B, Han F and Chen S: Musashi2 as a novel predictive
biomarker for liver metastasis and poor prognosis in colorectal
cancer. Cancer Med. 5:623–630. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scaltriti M and Baselga J: The epidermal
growth factor receptor pathway: A model for targeted therapy. Clin
Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maughan TS, Adams RA, Smith CG, Meade AM,
Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL,
et al: Addition of cetuximab to oxaliplatin-based first-line
combination chemotherapy for treatment of advanced colorectal
cancer: Results of the randomised phase 3 MRC COIN trial. Lancet.
377:2103–2114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li ZZ, Wang F, Zhang ZC, Wang F, Zhao Q,
Zhang DS, Wang FH, Wang ZQ, Luo HY, He MM, et al: Mutation
profiling in chinese patients with metastatic colorectal cancer and
its correlation with clinicopathological features and anti-EGFR
treatment response. Oncotarget. 7:28356–28368. 2016.PubMed/NCBI
|
|
8
|
Morris VK, Lucas FA, Overman MJ, Eng C,
Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P,
et al: Clinicopathologic characteristics and gene expression
analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal
cancer. Ann Oncol. 25:2008–2014. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang CW, Tsai HL, Chen YT, Huang CM, Ma
CJ, Lu CY, Kuo CH, Wu DC, Chai CY and Wang JY: The prognostic
values of EGFR expression and KRAS mutation in patients with
synchronous or metachronous metastatic colorectal cancer. BMC
Cancer. 13:5992013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shen Y, Han X, Wang J, Wang S, Yang H, Lu
SH and Shi Y: Prognostic impact of mutation profiling in patients
with stage II and III colon cancer. Sci Rep. 6:243102016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bottaro DP, Rubin JS, Faletto DL, Chan AM,
Kmiecik TE, Vande Woude GF and Aaronson SA: Identification of the
hepatocyte growth factor receptor as the c-met proto-oncogene
product. Science. 251:802–804. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Elliott VA, Rychahou P, Zaytseva YY and
Evers BM: Activation of c-Met and upregulation of CD44 expression
are associated with the metastatic phenotype in the colorectal
cancer liver metastasis model. Plos One. 9:e974322014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lorenzon L, Ricca L, Pilozzi E, Lemoine A,
Riggio V, Giudice MT, Mallel G, Fochetti F and Balducci G: Tumor
regression grades, K-RAS mutational profile and c-MET in colorectal
liver metastases. Pathol Res Pract. 213:1002–1009. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao P, Song YX, Wang ZN, Xu YY, Tong LL,
Sun JX, Yu M and Xu HM: Is the prediction of prognosis not improved
by the seventh edition of the TNM classification for colorectal
cancer? Analysis of the surveillance, epidemiology, and end results
(SEER) database. BMC Cancer. 13:1232013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yin H, Xu L and Yao HW: New opinions of
colorectal cancer in 2010. Chin J Practical Surg. 30:764–768.
2010.
|
|
16
|
Aras M, Erdil TY, Dane F, Gungor S, Ones
T, Dede F, Inanir S and Turoglu HT: Comparison of WHO, RECIST 1.1,
EORTC, and PERCIST criteria in the evaluation of treatment response
in malignant solid tumors. Nucl Med Commun. 37:9–15.
2016.PubMed/NCBI
|
|
17
|
Lupini L, Bassi C, Mlcochova J, Musa G,
Russo M, Vychytilova-Faltejskova P, Svoboda M, Sabbioni S, Nemecek
R, Slaby O and Negrini M: Prediction of response to anti-EGFR
antibody-based therapies by multigene sequencing in colorectal
cancer patients. BMC Cancer. 15:8082015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie G, Xie F, Wu P, Yuan X, Ma Y, Xu Y, Li
L, Xu L, Yang M and Shen L: The mutation rates of EGFR in non-small
cell lung cancer and KRAS in colorectal cancer of Chinese patients
as detected by pyrosequencing using a novel dispensation order. J
Exp Clin Cancer Res. 34:632015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao J, Wu H, Wang L, Zhang H, Duan H, Lu J
and Liang Z: Validation of targeted next-generation sequencing for
RAS mutation detection in FFPE colorectal cancer tissues:
Comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
BMJ Open. 6:article e009532. 2016. View Article : Google Scholar
|
|
20
|
Ma PC, Tretiakova MS, MacKinnon AC,
Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG,
Jagadeeswaran R, Krausz T, et al: Expression and mutational
analysis of MET in human solid cancers. Genes Chromosomes Cancer.
47:1025–1037. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fearon ER and Vogelstein B: A genetic
model for colorectal. tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bradley CA, Dunne PD, Bingham V, McQuaid
S, Khawaja H, Craig S, James J, Moore WL, McArt DG, Lawler M, et
al: Transcriptional upregulation of c-MET is associated with
invasion and tumor budding in colorectal cancer. Oncotarget.
7:78932–78945. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ogura T, Kakuta M, Yatsuoka T, Nishimura
Y, Sakamoto H, Yamaguchi K, Tanabe M, Tanaka Y and Akagi K:
Clinicopathological characteristics and prognostic impact of
colorectal cancers with NRAS mutations. Oncol Rep. 32:50–56. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yokota T, Ura T, Shibata N, Takahari D,
Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, et
al: BRAF mutation is a powerful prognostic factor in advanced and
recurrent colorectal cancer. Br J Cancer. 104:856–862. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Russo AL, Borger DR, Szymonifka J, Ryan
DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, et
al: Mutational analysis and clinical correlation of metastatic
colorectal cancer. Cancer. 120:1482–1490. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen Y, Wang J, Han X, Yang H, Wang S, Lin
D and Shi Y: Effectors of epidermal growth factor receptor pathway:
The genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in
colorectal cancer characteristics and personalized medicine. PLoS
One. 8:e816282013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hawkes E and Cunningham D: Relationship
between colorectal cancer biomarkers and response to epidermal
growth factor receptor monoclonal antibodies. J Clin Oncol.
28:e529–e531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kawazoe A, Shitara K, Fukuoka S, Kuboki Y,
Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, et al: A
retrospective observational study of clinicopathological features
of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with
metastatic colorectal cancer. BMC Cancer. 15:2582015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kafatos G, Niepel D, Lowe K,
Jenkins-Anderson S, Westhead H, Garawin T, Traugottová Z, Bilalis
A, Molnar E, Timar J, et al: RAS mutation prevalence among patients
with metastatic colorectal cancer: A meta-analysis of real-world
data. Biomark Med. 10.2217/bmm-2016-0358. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fujiyoshi K, Yamamoto G, Takahashi A, Arai
Y, Yamada M, Kakuta M, Yamaguchi K, Akagi Y, Nishimura Y, Sakamoto
H, et al: High concordance rate of KRAS/BRAF mutations and MSI-H
between primary colorectal cancer and corresponding metastases.
Oncol Rep. 37:785–792. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shoji H, Yamada Y, Taniguchi H, Nagashima
K, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, et
al: Clinical impact of c-MET expression and genetic mutational
status in colorectal cancer patients after liver resection. Cancer
Sci. 105:1002–1007. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Inno A, Di Salvatore M, Cenci T, Martini
M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca
LM, et al: Is there a role for IGF1R and c-MET pathways in
resistance to cetuximab in metastatic colorectal cancer? Clin
Colorectal Cancer. 10:325–332. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Matsui S, Osada S, Tomita H, Komori S,
Mori R, Sanada Y, Takahashi T, Yamaguchi K and Yoshida K: Clinical
significance of aggressive hepatectomy for colorectal liver
metastasis, evaluated from the HGF/c-Met pathway. Int J Oncol.
37:289–297. 2010.PubMed/NCBI
|
|
34
|
Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu
T, Sun J, Jiang H, Zhu Y, Zheng Y, et al: Molecular spectrum of
KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer
patients: analysis of 1,110 cases. Sci Rep. 5:186782015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Organ SL and Tsao MS: An overview of the
c-MET signaling pathway. Ther Adv Med Oncol. 3 1 Suppl:S7–S19.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
De Roock W, De Vriendt V, Normanno N,
Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations:
Implications for targeted therapies in metastatic colorectal
cancer. Lancet Oncol. 12:594–603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim MJ, Lee HS, Kim JH, Kim YJ, Kwon JH,
Lee JO, Bang SM, Park KU, Kim DW, Kang SB, et al: Different
metastatic pattern according to the KRAS mutational status and
site-specific discordance of KRAS status in patients with
colorectal cancer. BMC Cancer. 12:3472012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sun Y, Sun L, An Y and Shen X:
Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer
Development in a Xenograft Model. Med Sci Monit. 21:2316–2321.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Carson R, Celtikci B, Fenning C, Javadi A,
Crawford N, Carbonell LP, Lawler M, Longley DB, Johnston PG and Van
Schaeybroeck S: HDAC inhibition overcomes acute resistance to MEK
inhibition in BRAF-mutant colorectal cancer by downregulation of
c-FLIPL. Clin Cancer Res. 21:3230–3240. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Costa-Cabral S, Brough R, Konde A, Aarts
M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord
CJ, et al: CDK1 Is a synthetic lethal target for KRAS mutant
tumours. PloS One. 11:e01490992016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Slebos RJ, Kibbelaar RE, Dalesio O,
Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van
Zandwijk N, Mooi WJ, et al: K-ras oncogene activation as a
prognostic marker in adenocarcinoma of the lung. N Engl J Med.
323:561–565. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
NCCN Clinical Practice Guidelines in
Oncology_Colon Cancer, . Rectal Cancer Version 1. 2015.http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf29–08.
2014
|
